{"entity":{"id":"nct03709680","kind":"trial","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","aka":[],"tldr":"A phase 2 trial of Palbociclib, Temozolomide, FOLFIRI in ewing sarcoma and rhabdomyosarcoma, run by Pfizer, active and no longer recruiting.","summary":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors is a phase 2 interventional study registered as NCT03709680 by Pfizer, with 128 participants enrolled, started 2019-05-24 and due to reach its primary completion in 2024-08-26. Interventions recorded: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide. Conditions listed: Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03709680","url":"https://clinicaltrials.gov/study/NCT03709680"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ewing-sarcoma","rhabdomyosarcoma","medulloblastoma","dipg-dmg"],"sections":[],"technologies":["cdk46-inhibitor","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["palbociclib","temozolomide","folfiri","topotecan","cyclophosphamide"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03709680","phase":"2","setting":"PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS","sponsor":"Pfizer","participation":[{"nct":"NCT03709680","source":"https://clinicaltrials.gov/study/NCT03709680","fetchedAt":"2026-10-07T16:53:07.266Z","studySha256":"61f4de1992bfd7a2cab386e847fc52a377f449812ed79d5a9e9d330c991ca08b","overallStatus":"COMPLETED","lastUpdatePosted":"2026-10-07","leadSponsor":"Pfizer","collaboratorCount":1,"minimumAge":"2 Years","maximumAge":"20 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":128,"enrolmentType":"ACTUAL","siteCount":84,"recruitingSiteCount":0,"countries":["Brazil","Canada","Czechia","Germany","India","Poland","Slovakia","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2019-05-24","startedType":"actual","enrolled":128,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03709680/","neighbours":{"cancer":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}